Dr. Ian Mills is Chief Medical Officer at Sudo Biosciences. He also serves as an Entrepreneur-in-Residence with Frazier Life Sciences.

He was previously Chief Medical Officer at Outpost Medicine from 2017 to 2020. Prior to Outpost, Ian was at Mitsubishi Tanabe, where he was Head of Clinical Development. Prior to Mitsubishi, he was with Pfizer for more than 15 years in a variety of clinical and development leadership roles, most recently as Vice President and Global Clinical Head for the Innovative Pharma Business. Ian has provided leadership to projects across multiple therapeutic areas, including Genitourinary & Women’s Health, Gastroenterology, Inflammation & Immunology and Neurosciences, spanning Phases 1-4, including submission of five products for approval in major markets, and two FDA approvals.

Ian received his MA in Natural Sciences from Cambridge University and his medical degree (B.M., B.Ch.) from Oxford University. He was awarded a medical doctorate (D.M.) from Oxford for his research on the pathophysiology of overactive and neurogenic bladder. He is an accredited pharmaceutical physician and a Fellow of the Faculty of Pharmaceutical Medicine (FFPM) in the UK.